Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.93 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.93 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.93 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.93 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.93 |
| ▸ | SRC | P12931 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.93 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.90 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.86 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.86 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.86 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.86 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.82 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.82 |
| ▸ | LDHA | P00338 | 1/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.82 |
| ▸ | FBP1 | P09467 | 1/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL3459127 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL193645 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL28356 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL28358 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL193647 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL28204853 | 1.00 | P2RY1 (0.93) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL23752112 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL4594616 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL27523058 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL3498798 | 0.99 | P2RY1 (0.91) | P2RY1P2RX1P2RX3P2RY2P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11029457-A | — | — | None | — | — | JP | disclosed |
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | FERRER INTERNACIONAL, S.A. (ES) | 2026-01-27 | — | — | US | disclosed |
| CN-118516431-A | Novel method for producing oligonucleotides | 葛兰素史克知识产权开发有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-111479923-B | Novel method for producing oligonucleotides | 葛兰素史克知识产权开发有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-113784706-B | Multi-layered pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and B vitamins, their preparation and use | 菲尔若国际公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220160744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2022-05-26 | — | — | US | disclosed |
| EP-3965744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | Ferrer Internacional, S.A. (ES) | 2022-03-16 | — | — | EP | disclosed |
| CN-113784706-A | Multi-layered pharmaceutical or nutraceutical solid dosage form comprising pyrimidine and/or purine derivatives and B vitamins, preparation and use thereof | 菲尔若国际公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-104592338-B | A kind of method for synthesizing symmetric double ribonucleoside triphosphote, four phosphoric acid and five sodium ascorbyl phosphates | 江西科技师范大学 | 2017-09-19 | — | — | CN | disclosed |
| EP-2301555-B1 | CREAMY O/W EMULSION COMPOSITION AND PRODUCTION PROCESS THEREOF | OTSUKA PHARMA CO LTD (JP) | 2016-02-17 | — | — | EP | disclosed |
| CN-102046184-A | Cream-like O/W type emulsified composition and method for producing same | OTSUKA PHARMA CO LTD | 2011-05-04 | — | — | CN | disclosed |
| EP-2301555-A1 | CREAM-LIKE O/W TYPE EMULSIFIED COMPOSITION AND METHOD FOR PRODUCING SAME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| CN-100341486-C | Oil-in-water type emulsion composition and method for producing the same | OTSUKA PHARMA CO LTD (JP) | 2007-10-10 | — | — | CN | disclosed |
| EP-1342462-B1 | O/W EMULSION COMPOSITION AND METHOD OF PREPARING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-20060009415-A1 | Corneal epithelial migration promoter | NAKATA KATSUHIKO | 2006-01-12 | — | — | US | disclosed |
| US-6946436-B2 | O/W emulsion composition and method of preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-09-20 | — | — | US | disclosed |
| CN-1476318-A | Oil-in-water type emulsion composition and method for producing the same | ��V��ҩ��ʽ���� | 2004-02-18 | — | — | CN | disclosed |
| US-20040029761-A1 | O/W emulsion composition and method of preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1342462-A1 | O/W EMULSION COMPOSITION AND METHOD OF PREPARING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| JP-H1129457-A | SKIN COSMETIC | KANEBO LTD | 1999-02-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | P2RY10, TYMP, P2RY12 | P2RY1 14/4885P2RX1 22/4885P2RX3 21/4885 |
| US-20060009415-A1 | Corneal epithelial migration promoter | GPR17, UMPS, P2RY6 | P2RY1 4/4885P2RX1 20/4885P2RX3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.